Literature DB >> 2153058

Variation in the loss of O6-methylguanine-DNA methyltransferase during immortalization of human fibroblasts.

M H Green1, P Karran, J E Lowe, A Priestley, C F Arlett, L Mayne.   

Abstract

We have examined O6-methylguanine-DNA methyltransferase (MT) activity in four human fibroblast cell lines during immortalization. Transfection of primary fibroblasts with the plasmid pSV3gpt or pSV3neo, which encode the SV40 large T antigen, confers a transformed phenotype but not immediate immortality. After a period of growth (pre-crisis) the cells enter a quiescent phase (crisis) from which an immortal clone of cells eventually grows out. From measurements of MT activity in extracts of cells taken at different defined stages of the immortalization process, we conclude that the establishment of a Mex- (MT-deficient) cell population is not specifically associated with cellular transformation or with any particular stage of immortalization. It appears that in different cell populations the change from Mex+ to Mex- may occur at different times during the immortalization process and that the change may be very abrupt.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153058     DOI: 10.1093/carcin/11.1.185

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  2 in total

1.  Normal expression of thymidine kinase and O6-methylguanine-DNA methyltransferase in cultured fibroblasts from individuals with hereditary galactokinase deficiency.

Authors:  C Stephenson; M Brivet; M Gautier; J Deschatrette; R Gitzelmann; P Karran
Journal:  Biochem Genet       Date:  1991-04       Impact factor: 1.890

2.  Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines.

Authors:  J F Costello; B W Futscher; R A Kroes; R O Pieper
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.